Clinical-stage biopharmaceutical firm Neurotech International (ASX:NTI) has reached a transformative regulatory milestone, receiving Human Research Ethics Committee approval to commence its Beyond Harmony Phase 3 clinical study.
The pivotal trial will evaluate the efficacy and safety of NTI164, the company's proprietary biopharmaceutical formulation, in pediatric patients diagnosed with autism spectrum disorder Levels 2 and 3.
The "Beyond Harmony" study serves as a registration-directed trial, specifically designed to meet the rigorous data requirements for market authorisation submissions to the Therapeutic Goods Administration in Australia and the US Food and Drug Administration.
The study’s framework is built upon successful Phase 2 results, which demonstrated statistically significant improvements in core ASD symptoms and caregiver-reported quality-of-life metrics.
By targeting "Level 2" (requiring substantial support) and "Level 3" (requiring very substantial support) patients, Neurotech is addressing a significant unmet need in the global pediatric neurology market.
The study will leverage a sophisticated network of satellite clinical sites. Initial site activation and participant recruitment are slated to begin immediately across Australia, with a progressive rollout into the United States planned to follow.
At the time of reporting, Neurotech International's share price was $0.014.